Involvement of Cholesterol-Rich Lipid Rafts in Interleukin-6-Induced Neuroendocrine Differentiation of LNCaP Prostate Cancer Cells

Endocrinology

Volumn 145, Issue 2, 2004, Pages 613-619

  Kim, Jayoung ^a   Adam, Rosalyn M ^a   Solomon, Keith R ^a   Freeman, Michael R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ENOLASE; FILIPIN; FLOTILLIN 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MEMBRANE LIPID; PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL NUCLEUS; CELL SPECIFICITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; MALE; MEMBRANE COMPONENT; MEMBRANE DAMAGE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR OCCUPANCY; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; CELL MEMBRANE; CELL NUCLEUS; CHOLESTEROL; DETERGENTS; DNA-BINDING PROTEINS; FILIPIN; GENE EXPRESSION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; INTERLEUKIN-6; MALE; MEMBRANE LIPIDS; MEMBRANE PROTEINS; NEUROSECRETORY SYSTEMS; OCTOXYNOL; PHOSPHOPYRUVATE HYDRATASE; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0842269851     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0772     Document Type: Article

References (48)

1. Abrahamsson PA 1999 Neuroendocrine differentiation in prostatic carcinoma. Prostate 39:135-148
2. Cox ME, Deeble PD, Lakhani S, Parsons SJ 1999 Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 59:3821-3830
3. Deeble PD, Murphy DJ, Parsons SJ, Cox ME 2001 Interleukin-6-and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21:8471-8482
4. Jongsma J, Oomen MH, Noordzij MA, Romijn JC, van Der Kwast TH, Schroder FH, van Steenbrugge GJ 2000 Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 42: 34-44
5. Regnauld K, Nguyen QD, Vakaet L, Bruyneel E, Launay JM, Endo T, Mareel M, Gespach C, Emami S 2002 G-protein α(olf) subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. Oncogene 21:4020-4031
6. Kim J, Adam RM, Freeman MR 2002 Activation of the ERK mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 62:1549-1554
7. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ 2001 A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 61:2239-2249
8. Cox ME, Deeble PD, Bissonette EA, Parsons SJ 2000 Activated 3′, 5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 275:13812-13818
9. Juarranz MG, Bolanos O, Gutierrez-Canas I, Lerner EA, Robberecht P, Carmena MJ, Prieto JC, Rodriguez-Henche N 2001 Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell Signal 13:887-894
10. Spiotto MT, Chung TD 2000 STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42:186-195
11. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R 1999 Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 162:1800-1805
12. Bang YJ, Pirniia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Meyers CE, Trepel JB 1994 Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 91: 5330-5334
13. Adam RM, Kim J, Lin J, Orsola A, Zhuang L, Rice DC, Freeman MR 2002 Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 143:4599-4608
14. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC 1999 Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 161:182-187
15. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP 1999 Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41:127-133
16. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M 2000 Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6:2702-2706
17. Mori S, Murakami-Mori K, Bonavida B 1999 Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 257:609-614
18. Leonard WJ 2001 Role of JAK kinases and STATs in cytokine signal transduction. Int J Hematol 73:271-277
19. Darnell Jr JE 1997 STATs and gene regulation. Science 277:1630-1635
20. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L 1998 Interleukin-6-type cytokine signalling through the gp130/JAK/STAT pathway. Biochem J 334:297-314
21. Ju H, Venema VJ, Liang H, Harris MB, Zou R, Venema RC 2000 Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signalling proteins in plasmalemmal caveolae. Biochem J 351:257-264
22. Sehgal PB, Guo GG, Shah M, Kumar V, Patel K 2002 Cytokine signaling: STATS in plasma membrane rafts. J Biol Chem 277:12067-12074
23. Pike LJ 2003 Lipid rafts: bringing order to chaos. J Lipid Res 44:655-667
24. Simons K, Toomre D 2000 Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1:31-39
25. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H 2002 Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94:929-933
26. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC 2001 Caveolin-1 mediates testosterone-stimulated survival/ clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61:4386-4392
27. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC 2000 Elevated caveolin-1 levels in African-American versus White-American prostate cancer. Clin Cancer Res 6:3430-3433
28. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC 1998 Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4:1873-1880
29. Yang G, Truong LD, Wheeler TM, Thompson TC 1999 Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59:5719-5723
30. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP 2001 Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 276:13442-13451
31. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR 2002 Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 62:2227-2231
32. Solomon KR, Mallory MA, Finberg RW 1998 Determination of the non-ionic detergent insolubility and phosphoprotein associations of glycosylphosphatidylinositol-anchored proteins expressed on T cells. Biochem J 334:325-333
33. Huo H, Guo X, Hong S, Jiang M, Liu X, Liao K 2003 Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction. J Biol Chem 278:11561-11569
34. Ushio-Fukai M, Hilenski L, Santanam N, Becker PL, Ma Y, Griendling KK, Alexander RW 2001 Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem 276:48269-48275
35. Sadir R, Lambert A, Lortat-Jacob H, Morel G 2001 Caveolae and clathrin-coated vesicles: two possible internalization pathways for IFN-γ and IFN-γ receptor. Cytokine 14:19-26
36. Engelman JA, Lee RJ, Kamezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG, Lisanti MP 1998 Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273:20448-20455
37. Li S, Couet J, Lisanti MP 1996 Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 271:29182-29190
38. Roy S, Luetterforst R, Harding A, Apolloni A, Etheridge M, Stang E, Rolls B, Hancock JF, Parton RG 1999 Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol 1:98-105
39. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC 2002 Stat3 activation in prostatic carcinomas. Prostate 51:241-246
40. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R 2002 Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62:6659-6666
41. DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB, Gao AC 2002 Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 52:123-129
42. Swyer GIM 1942 The cholesterol content of normal and enlarged prostates. Cancer Res 2:372-375
43. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ 2001 Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7:158-167
44. Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, Kang WK, Wang XF, Kim SJ, Trepel JB 1998 Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 273:10618-10623
45. Park C, Lee I, Kang WK 2001 Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 22:1727-1731
46. Coffey DS 2001 Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology 57:31-38
47. Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, Giovannucci E 2001 A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 12:557-567
48. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyorala K, Wedel H 2000 Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86:257-262